Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis
Authors:
- Eveliina PollariEPEveliina Pollari
- Ekaterina SavchenkoESEkaterina Savchenko
- Merja JaronenMJMerja Jaronen
- Katja KanninenKKKatja Kanninen
- Tarja MalmTMTarja Malm
- Sara WojciechowskiSWSara Wojciechowski
- Toni AhtoniemiTAToni Ahtoniemi
- Gundars GoldsteinsGGGundars Goldsteins
- Raisa GiniatullinaRGRaisa Giniatullina
- Rashid GiniatullinRashid Giniatullin
- Jari KoistinahoJKJari Koistinaho
- Johanna MaggaJMJohanna Magga
Open Access
- 28 June 2011
- journal article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 8 (1) , 74
Abstract
Background: Granulocyte colony stimulating factor (GCSF) is protective in animal models of various neurodegenerative diseases. We investigated whether pegfilgrastim, GCSF with sustained action, is protective in a mouse model of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease with manifestations of upper and lower motoneuron death and muscle atrophy accompanied by inflammation in the CNS and periphery. Methods: Human mutant G93A superoxide dismutase (SOD1) ALS mice were treated with pegfilgrastim starting at the presymptomatic stage and continued until the end stage. After long-term pegfilgrastim treatment, the inflammation status was defined in the spinal cord and peripheral tissues including hematopoietic organs and muscle. The effect of GCSF on spinal cord neuron survival and microglia, bone marrow and spleen monocyte activation was assessed in vitro. Results: Long-term pegfilgrastim treatment prolonged mutant SOD1 mice survival and attenuated both astro- and microgliosis in the spinal cord. Pegfilgrastim in SOD1 mice modulated the inflammatory cell populations in the bone marrow and spleen and reduced the production of pro-inflammatory cytokine in monocytes and microglia. The mobilization of hematopoietic stem cells into the circulation was restored back to basal level after long-term pegfilgrastim treatment in SOD1 mice while the storage of Ly6C expressing monocytes in the bone marrow and spleen remained elevated. After pegfilgrastim treatment, an increased proportion of these cells in the degenerative muscle was detected at the end stage of ALS. Conclusions: GCSF attenuated inflammation in the CNS and the periphery in a mouse model of ALS and thereby delayed the progression of the disease. This mechanism of action targeting inflammation provides a new perspective of the usage of GCSF in the treatment of ALS.Keywords
This publication has 76 references indexed in Scilit:
- CNS-targeted Viral Delivery of G-CSF in an Animal Model for ALS: Improved Efficacy and Preservation of the Neuromuscular UnitMolecular Therapy, 2011
- Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic miceProceedings of the National Academy of Sciences, 2009
- Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyondJournal of Cell Biology, 2009
- Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cellsProceedings of the National Academy of Sciences, 2009
- Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesisJournal of Experimental Medicine, 2007
- Hematopoietic growth factors pass through the blood–brain barrier in intact ratsExperimental Neurology, 2007
- Early vulnerability to ischemia/reperfusion injury in motor terminals innervating fast muscles of SOD1-G93A miceExperimental Neurology, 2007
- Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2006
- Nitric Oxide as a Bioregulator of ApoptosisBiochemical and Biophysical Research Communications, 2001
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993